Total amount: € 0,00
Official Journal of the Italian Society of Social Psychiatry
Indexed/Abstracted in: EMBASE, e-psyche, PsycINFO, Scopus
Online ISSN 1827-1731
Therapies with nicotinic acid and nicotinamide have been advocated as primary or adjuvant therapies in schizophrenia for many years. In depressive syndrome the research with nicotinic acid and nicotinamide has not been broad.
In schizophrenic disease these drugs (nicotinic acid and nicotinamide) act in the body as obligate methyl acceptors and thus may reduce the availability of methyl groups for the formation of schizogenic substances. In depressive syndrome, the mechanism of action of nicotinamide is also known. In our research, therapeutic effect of neuroleptics and paroxetine (SSRI) is augmented by nicotinamide in 40-50% of the cases.